Uğur Özkerim· @UOzkerim · X·· 14 小时前评分70
正文 · 原文
🚨 Impressive results from #ESMO2026!
Phase III DeLLphi-305: Tarlatamab + durvalumab vs durvalumab alone as 1L maintenance in ES-SCLC:
🔹 Median OS: 21.1 vs 12.7 months (HR 0.42)
🔹 Median PFS: 7.4 vs 1.9 months (HR 0.34)
🔹 ORR: 26.4% vs 4.1%
🔥 Practice-changing potential!
#LungCancer #SCLC
@OncoAlert @weoncologists @StephenVLiu @GlopesMd @ManuelDomine
92 浏览 · 4 赞 · 3 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Uğur Özkerim · x.com